Traws Pharma (Traws Pharma) Earnings per Share (Diluted) : $-0.91 (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Earnings per Share (Diluted)?

Traws Pharma's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.20. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.91.

Traws Pharma's EPS (Basic) for the three months ended in Dec. 2023 was $-0.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.91.

Traws Pharma's EPS without NRI for the three months ended in Dec. 2023 was $-0.20. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.91.

During the past 3 years, the average EPS without NRIGrowth Rate was 25.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 60.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 67.30% per year.

During the past 13 years, Traws Pharma's highest 3-Year average EPS without NRI Growth Rate was 84.90% per year. The lowest was -18.10% per year. And the median was 61.10% per year.

Traws Pharma Earnings per Share (Diluted) Historical Data

The historical data trend for Traws Pharma's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Earnings per Share (Diluted) Chart

Traws Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-22.35

-2.17

-0.96

-0.91

-0.90

Traws Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-0.26	-0.28	-0.20	-0.23	-0.20

Competitive Comparison of Traws Pharma's Earnings per Share (Diluted)

For the Biotechnology subindustry, Traws Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Traws Pharma's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Traws Pharma's PE Ratio falls into.

Traws Pharma Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Traws Pharma's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-18.948	-	0)	/	20.989
	=	-0.90

Traws Pharma's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-4.184	-	0)	/	21.012
	=	-0.20

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.91

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Traws Pharma (NAS:TRAW) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Traws Pharma Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Traws Pharma (Traws Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (NAS:TRAW) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

0T2:Germany

Address

12 Penns Trail, Newtown, PA, USA, 18940

Website

https://www.onconova.com

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Executives

Victor M Moyo	officer: CHIEF MEDICAL OFFICER	12 PENNS TRAIL, NEWTOWN PA 18940
Trafford Clarke	director	12 PENNS TRAIL, NEWTOWN PA 18940
Peter Atadja	director	12 PENNS TRAIL, NEWTOWN PA 18940
Abraham N. Oler	officer: VP Corp Dev & Gen Counsel	C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052
Steven M Fruchtman	officer: Chief Medical Officer	375 PHEASANT RUN, NEWTOWN PA 18940
James J Marino	director	C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Gelder Mark S. Md	officer: Chief Medical Officer	C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark Patrick Guerin	officer: Chief Accounting Officer	375 PHEASANT RUN, NEWTOWN PA 18940
Mary Teresa Shoemaker	director	375 PHEASANT RUN, NEWTOWN PA 18940
Michael B Hoffman	director	1 GREENWICH OFFICE PARK, GREENWICH CT 06831
E Premkumar Reddy	director	375 PHEASANT RUN, NEWTOWN PA 18940
Jerome Groopman	director	C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922
Viren Mehta	director	OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747
Tyndall Capital Partners L P	10 percent owner	150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022